Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Blood Transfusion01:15

Blood Transfusion

Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Front-of-package nutrition labeling and obesity implications.

American journal of preventive medicine·2011
Same author

Random plasma glucose measurement may improve the diagnostic specificity of highly sensitive troponin in the emergency department.

International journal of cardiology·2011
Same author

Serum concentration of neopterin on admission does not improve the diagnostic performance of highly-sensitive troponin I.

Clinical chemistry and laboratory medicine·2011
Same author

Intermittent hypobaric hypoxia applicability in myocardial infarction prevention and recovery.

Journal of cellular and molecular medicine·2011
Same author

Fibrinogen replacement therapy: a critical review of the literature.

Blood transfusion = Trasfusione del sangue·2011
Same author

Cardiac troponins and physical exercise. It's time to make a point.

Biochemia medica·2011
Same journal

Cardiovascular disease and miRNA.

Advances in clinical chemistry·2026
Same journal

RNA biomarkers in antidoping.

Advances in clinical chemistry·2026
Same journal

Biomarkers for assessing magnesium status.

Advances in clinical chemistry·2026
Same journal

Advances in microfluidic extracellular vesicle technology.

Advances in clinical chemistry·2026
Same journal

Chronic low-grade inflammation in vegetarians and vegans: Biomarker evidence and methodological considerations.

Advances in clinical chemistry·2026
Same journal

Biomarkers in heart failure.

Advances in clinical chemistry·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Acquired hemophilia A.

Massimo Franchini1, Giuseppe Lippi

  • 1Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy mfranchini@ao.pr.it

Advances in Clinical Chemistry
|August 31, 2011
PubMed
Summary
This summary is machine-generated.

Acquired hemophilia A is a rare bleeding disorder caused by autoantibodies against coagulation factor VIII. This review summarizes current knowledge on diagnosing and treating this serious condition.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: May 29, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Area of Science:

  • Hematology
  • Immunology
  • Internal Medicine

Background:

  • Acquired hemophilia A (AHA) is a rare, life-threatening hemorrhagic disorder.
  • It involves autoantibodies targeting coagulation factor VIII.
  • Fifty percent of cases are idiopathic, while the rest are linked to pregnancy, autoimmune diseases, cancers, or drugs.

Purpose of the Study:

  • To review current knowledge on the diagnostic aspects of acquired hemophilia A.
  • To summarize the therapeutic strategies for acquired hemophilia A.
  • To provide a comprehensive overview of AHA for clinicians and researchers.

Main Methods:

  • Literature review of diagnostic methods for AHA.
  • Analysis of therapeutic approaches for AHA.
  • Synthesis of current data on idiopathic and associated cases of AHA.

Main Results:

  • AHA diagnosis relies on clinical suspicion and laboratory tests, including a prolonged activated partial thromboplastin time (aPTT) and low factor VIII activity.
  • Treatment involves factor VIII concentrate or bypassing agents for acute bleeding and immunosuppression to eradicate autoantibodies.
  • Identifying and managing associated conditions is crucial for successful treatment.

Conclusions:

  • Acquired hemophilia A requires prompt diagnosis and multidisciplinary management.
  • Effective treatment strategies exist but necessitate individualized approaches.
  • Further research into optimal immunosuppressive therapies and long-term outcomes is warranted.